Marilyn Kehry

This inventor holds 14 USPTO granted patents and 17 published patent applications, plus 4 CIPO patents and 4 EPO patents, primarily in Immunotherapy Antibodies. Top assignees: Anaptysbio, Inc., Momenta Pharmaceuticals, Inc., Tesaro, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marilyn Kehry. Retrieved from https://idiyas.com/inventor/marilyn-kehry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 18)

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 53(Granted Patents)

Company Filing History:

Momenta Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

PD-1 Agonist

FcRn Antibodies

TIM-3

LAG-3

Anti-idiotypic Antibodies

Immunotherapy

Cancer Treatment

Monoclonal Antibodies

Protein Binding

Therapeutic Applications

Immune Modulation

Antibody Development

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12742010 - PD-1 AGONIST AND METHOD OF USING SAME (2026-09-22),

2. 12655209 - FcRn Antibodies and Methods of Use Thereof (2026-06-16),

3. 11753472 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2023-09-12),

4. 11732047 - FcRn antibodies and methods of use thereof (2023-08-22),

5. 11352427 - Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3) (2022-06-07),

6. 11345751 - FcRn antibodies and methods of use thereof (2022-05-31),

7. 11155624 - Antibodies directed against programmed death-1 (PD-1) (2021-10-26),

8. 10836824 - Antibodies directed against lymphocyte activation gene 3 (LAG-3) (2020-11-17),

9. 10738117 - Antibodies directed against programmed death-1 (PD-1) (2020-08-11),

10. 10676526 - FcRn antibodies and methods of use thereof (2020-06-09),

11. 10508149 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2019-12-17),

12. 10428145 - PD-1 binding proteins and methods of use thereof (2019-10-01),

13. 10150817 - Rapid generation of anti-idiotypic antibodies (2018-12-11),

14. 9815897 - Antibodies directed against programmed death-1 (PD-1) (2017-11-14),

Title: **Innovative Contributions of Inventor Marilyn Kehry in Biopharmaceuticals**

Introduction

Marilyn Kehry is a renowned inventor based in San Diego, California, with an impressive portfolio of 12 patents focusing on advancements in biopharmaceuticals. Her pioneering work has significantly contributed to the field of immunology and therapeutic development, showcasing her dedication to addressing complex health challenges.

Latest Patents

Among her latest patents is the development of antibodies directed against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3). This invention provides anti-TIM-3 antibodies characterized by specific immunoglobulin heavy chain and light chain polypeptide sequences. These antibodies are designed to treat disorders responsive to TIM-3 inhibition, such as various forms of cancer, infectious diseases, and autoimmune conditions.

Another noteworthy patent involves FcRn antibodies and their potential applications. This invention features antibodies with high binding affinity to the human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are valuable for promoting clearance of autoantibodies, suppressing antigen presentation, and blocking immune responses, making them beneficial in the treatment of immunological diseases, particularly autoimmune disorders.

Career Highlights

Throughout her career, Kehry has made significant strides in the biopharmaceutical sector. She has held influential positions at companies like Anaptysbio, Inc. and Momenta Pharmaceuticals, Inc., where her expertise in immunology and antibody development has driven innovations integral to addressing numerous health challenges.

Collaborations

Marilyn Kehry has worked alongside notable colleagues such as David J King and Leona E Ling. Their collaborative efforts have fostered a dynamic environment for research and development, enhancing the impact of her inventions and pushing the boundaries of current therapeutic methods.

Conclusion

Marilyn Kehry exemplifies the spirit of innovation in the biopharmaceutical industry. Her contributions through her patents represent a vital step forward in developing targeted therapies for serious health conditions. As she continues her work, Kehry's inventions hold the promise of making a meaningful impact on the lives of many patients.

Profile summary based on public USPTO records.